Incyte Names New Member to Its Board of Directors
Incyte Corporation (INCY)
Last incyte corporation earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
incyte.com/ir/investor-overview.aspx
Company Research
Source: Business Wire
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announces the appointment of Katherine High, M.D., as a new member of the Board of Directors, effective March 25, 2020.“We are delighted to announce that Kathy is joining the Incyte Board of Directors. Her scientific expertise and extensive leadership experience will support and enhance Incyte’s continued growth,” said Hervé Hoppenot, Chief Executive Officer, Incyte.“This is an exciting time to be joining Incyte – with the potential for three new product approvals this year, the Company’s discovery, development and strategic focus continue to drive the delivery of innovative solutions for patients in need,” said Dr. High. “I look forward to joining what is already an immensely talented and diverse team.”From 2014 to 2020, Dr. High held several key executive positions at Spark Therapeutics, Inc., a gene therapy company, including President, Head of Research and Development and Chief Scientific Officer. Prior to joining Spark,
Show less
Read more
Impact Snapshot
Event Time:
INCY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INCY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INCY alerts
High impacting Incyte Corporation news events
Weekly update
A roundup of the hottest topics
INCY
News
- Incyte Gains 12.7% Year to Date: How Should You Play the Stock? [Yahoo! Finance]Yahoo! Finance
- Multiple Late-Breaking Data Presentations from Incyte’s Dermatology Portfolio will be Featured at the European Academy of Dermatology and Venereology (EADV) 2024 CongressBusiness Wire
- Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease [Yahoo! Finance]Yahoo! Finance
- Incyte Downgraded - Analyst Notes Intense Competition, Particularly In Larger Markets [Yahoo! Finance]Yahoo! Finance
- Incyte Co. (NASDAQ: INCY) had its "hold" rating re-affirmed by analysts at Truist Financial Co.. They now have a $74.00 price target on the stock, down previously from $83.00.MarketBeat
INCY
Earnings
- 7/30/24 - Miss
INCY
Sec Filings
- 9/16/24 - Form 4
- 9/16/24 - Form 4
- 9/13/24 - Form 144
- INCY's page on the SEC website